GBI Research’s latest report Pharmaceutical Lifecycle Management Strategies in 2017 provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world. The pharmaceutical industry remains highly competitive and lucrative, and companies are investing significant time and resources into implementing strategies aimed at preserving the revenue streams of their products by extending patent life, delaying competition or slowing the pace of revenue loss following the end of market exclusivity.
The study, delivered in the form of an 82-slide PowerPoint presentation investigates a wide range of commercial, developmental, legal and regulatory strategies. This report format allows you to easily assemble high-quality presentations and research material to meet a variety of corporate requirements. Our research deep dives into the rationale for implementing LCM strategies, as well as the challenges, risks and commercial opportunities they represent. Moreover, detailed case studies showcasing recent real-world examples of LCM strategies will enable understanding of the key factors that determined their success. Information leveraged from our robust industry-leading database also highlights strategies being implemented for products currently in development.
The pharmaceutical industry will continue to face a wide range of challenges in the coming years, including patent cliffs, declining productivity, intensifying levels of competition from generic and biosimilar manufacturers, low reimbursement levels and stricter regulatory policies. Careful LCM planning will continue to be a crucial element of the industry’s ability to answer these problems.
GBI Research conducted extensive research to provide a comprehensive understanding of the LCM strategies being implemented by players in the pharmaceutical industry. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising commercial areas in the market and exploit key business opportunities.
What is driving the need for effective LCM strategies in the pharmaceutical industry?
What are the most common LCM strategies being implemented?
What are the business opportunities and commercial rewards arising from the implementation of LCM strategies?
What are the key factors that impact the choice of LCM strategy?
What strategies have Big Pharma companies implemented in recent years to preserve revenues and market share?
Reasons To Buy
This report will allow you to:
Gain insights into the rationale for implementing LCM strategies, alongside their key challenges, risks and potential benefits.
Understand the key challenges that the pharmaceutical industry has been facing in recent years
Assess real-world examples of successful strategies implemented in the past, and the key factors that determined their success.
Obtain information on strategies for products currently in development.
Table of Contents
2. Executive Summary
3. Introduction to Pharmaceutical Lifecycle Management Strategies
3.1 The Pharmaceutical Product Lifecycle Curve
3.2 Key Objectives of Life Cycle Management Strategies in the Pharmaceutical Industry
3.3 What is Driving the Need for Effective Lifecycle Management Strategies in the Pharmaceutical Industry?
3.4 Classification and Benefits of Different Lifecycle Management Strategies for Pharma
3.5 Business Opportunities Created by LCM Strategies
3.6 Factors Impacting Choice of Lifecycle Strategies
The Europe Digital Camera Head for Endoscopes Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Digital Camera Head for Endoscopes industry.
The re ...Read More
The Global Dental Laboratory Handpieces Consumption 2016 Market Research Report is a professional and in-depth study on the current state of the Dental Laboratory Handpieces market.
First, the report ...Read More
Cardiovascular disease (CVD) covers a range of difference diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dys ...Read More
Pain, and in particular chronic pain, is a significant global health issue. While pain is not considered a disease in its own right, there is a growing body of evidence that substantiates chronic pain ...Read More
Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare a ...Read More
Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related death (Globocan, 2012). Currently, the range of therapi ...Read More
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a ...Read More
Immunology is a large therapy area characterized by disorders of the immune system – specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or a ...Read More
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced diseas ...Read More
Published By : GBI Research
For support please contact: US Toll Free
+1 888-789-6604 Asia Pacific
To receive alerts about an update, future offers and discounts on this report, signup here. Email ID